SEC 13F Intelligence

Duquesne Family Office LLC / ALNY

Duquesne Family Office LLC’s Alnylam Pharmaceuticals Inc Position

Does Duquesne Family Office LLC own Alnylam Pharmaceuticals Inc (ALNY)? Not currently — the last reported position was 88.9K shares worth $21M in Q4 2022; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$21M
Q4 2022
Shares
88.9K
% of Portfolio
+1.05%
Quarters Held
7
position exited

Position History ALNY

Reported value by quarter
Q4 ’19: $13MQ4 ’19Q1 ’20: $40MQ1 ’20Q2 ’20: $55MQ2 ’20Q3 ’20: $54MQ3 ’20Q1 ’22: $10MQ1 ’22Q3 ’22: $18MQ3 ’22Q4 ’22: $21MQ4 ’22filingsflow.com
QuarterSharesValue% of Portfolio
Q4 202288.9K$21M+1.05%
Q3 202288.9K$18M+1.01%
Q1 202263.9K$10M+0.45%
Q3 2020368.4K$54M+1.56%
Q2 2020368.4K$55M+1.67%
Q1 2020368.4K$40M+1.63%
Q4 2019116.2K$13M+0.39%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Duquesne Family Office LLC’s full portfolio or all institutional holders of ALNY.